In a research note on uniQure titled "Seeking Alpha in a High Beta Environment," H.C. Wainwright analyst Debjit Chattopadhyay says "enough with the discount already!" uniQure, along with other gene therapy and gene editing peers, could emerge as a "compelling" stock for the long run as healthcare evolves to a differentiated and value-based commercial market, Chattopadhyay tells investors in a research note. The analyst believes the company's positioning to be the first to commercialize a once-and-done solution for Hemophilia B gives it an advantage. Chattopadhyay recommends investors initiate or add to positions in uniQure.